Haffkine Institute gets approval for BCG trial
The Haffkine Institute got permission to run clinical trials of the anti-tuberculosis Bacillus Calmette-Guérin (BCG) vaccine to treat Covid-19 patients. The trials will be conducted at BJ Medical College, Pune.
The institute in Mumbai’s Parel had submitted the proposal to the Drug Controller General of India (DCGI) last month as a therapeutic treatment. “The vaccine helps to improve the immune system among people, so it is believed that it can be used as a therapeutic treatment for patients with Covid-19. Preliminary research has shown that it has helped to neutralise the virus to some extent,” said Dr. Sanjay Mukherjee, secretary, Medical Education and Drugs Department (MEDD).
Around 35 people with moderate and severe infection will be part of the trial.
Dr. Usha Padmanabhan who currently heads the Department of Cell Biology at Haffkine Institute will be in-charge of the trial. Dr Rajesh Deshmukh, managing director of the Institute said, “Unlike other new drugs, it would be easier to treat patients as this vaccine is already available in markets. We have already set up the laboratory for the trial at the college.”
Enter your email to get our daily newsletter in your inbox
- A bench of Chief Justice D N Patel and Justice Jasmeet Singh said the simple mechanism available with the petitioner is to unsubscribe to those emails.
- The Ease of Living Index was first launched in 2018 and is based on indicators across 15 evaluation criteria.
- Geeta went missing 20 years ago and reached Lahore, where she was found sitting alone in Samjhauta express in the year 2000.
- Here are today’s top news, analysis, and opinion. Know all about the latest news and other news updates from Hindustan Times.